Document is current
Any future updates will be listed below
-
Authors
Middleton, Gary
Robbins, Helen L.
Fletcher, Peter
Savage, Joshua https://orcid.org/0000-0003-0599-0245
Mehmi, Manita https://orcid.org/0000-0001-8220-9331
Summers, Yvonne
Greystoke, Alastair
Steele, Nicola
Popat, Sanjay
Jain, Pooja https://orcid.org/0000-0002-0645-8026
Spicer, James
Cave, Judith
Shaw, Paul
Gilligan, David
Power, Danielle
Fennell, Dean
Bajracharya, Maya
McBride, David J.
Maheswari, Uma
Frankell, Alexander M.
Swanton, Charles https://orcid.org/0000-0002-4299-3018
Beggs, Andrew D.
Billingham, Lucinda
- License Information
-
More Information
Article History
Received: 30 July 2024
Accepted: 10 February 2025
First Online: 11 March 2025
Competing interests
: G.M. received research funding from AstraZeneca and speaker bureau fees. Y.S. received an honorarium from AstraZeneca for advisory boards and educational events. A.G. and J.S.p received an honorarium from AstraZeneca for advisory boards. S.P. received consultancy and speaker bureau fees from AstraZeneca. P.J. received funding and consultancy honorarium from AstraZeneca. P.S., D.G. and D.F. received honorariums from AstraZeneca. M.B., D.M.B. and U.M. are employees of Illumina Cambridge Ltd. A.M.F. is a co-inventor on a patent application to determine methods and systems for tumour monitoring (PCT/EP2022/077987). A.D.B. received research funding from AstraZeneca. C.S. acknowledges grant support and honorarium from AstraZeneca and is an AstraZeneca advisory board member; honorarium from Illumina; is listed as an inventor on a European patent application relating to assay technology to detect tumour recurrence (PCT/GB2017/053289), the patent has been licensed to commercial entities and, under his terms of employment, C.S. is due a revenue share of any revenue generated from such license(s); holds patents relating to targeting neoantigens (PCT/EP2016/059401), identifying patient response to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221), identifying patients who respond to cancer treatment (PCT/GB2018/051912), a US patent relating to detecting tumour mutations (PCT/US2017/28013), methods for lung cancer detection (US20190106751A1) and both a European and US patent related to identifying insertion/deletion mutation targets (PCT/GB2018/051892) and is listed as a co-inventor on a patent application to determine methods and systems for tumour monitoring (PCT/EP2022/077987) and is a named inventor on a provisional patent protection related to a ctDNA detection algorithm. All other authors declare no relevant potential conflicts of interest.
